Full Description
Ten years have elapsed since the publication in 1978 of Vol. 49 of the Handbook of Experimental Pharmacology [41], a toOO-page survey of the data then available on Ergot Alkaloids and Related Compounds. A booklet published in 1979 presented the in formation on one of these compounds, namely co-dergocrine (Hydergine@), as extracted from the Handbook and updated to take the latest developments into account [42]. Co-dergocrine had at the time been on the market for 30 years and had given rise to over 2000 papers, so that one might have felt justified in thinking that its scientific history had virtually come to an end. It has now become obvious that such a view would have been wide of the mark. Research on the pharmacology and clinical pharmacology of co-dergocrine has remained as active as ever. The resulting obsolescence of the 1979 booklet made necessary the preparation of the present version. Like its predecessor, it is intended as an inventory of findings and facts rather than a work dealing with their interpretation.
Contents
I. Introduction and Background Information.- II. Basic Pharmacologic Properties: Peripheral Effects on Neurotransmission.- 1. Actions at Adrenoceptors.- 2. Actions at Dopamine Receptors.- 3. Actions at Serotonin (5-HT) Receptors.- 4. Miscellaneous and Unspecific Effects.- III. Basic Pharmacologic Properties: Central Effects.- 1. Effects on Neurotransmission.- 2. Effects on Brain Enzymes and Metabolism.- 3. Effects on Cerebral Blood Flow.- 4. Other Effects.- 5. Conclusions.- IV. Effects of Co-Dergocrine on the Cardiovascular System.- V. Effects of Co-Dergocrine on Other Organs and Cells.- 1. Effects on the Uterus.- 2. Effects on the Kidney.- 3. Effects on Blood Platelets.- VI. The Clinical Pharmacology of Co-Dergocrine in Age-Related Cerebral Insufficiency.- 1. Cerebral Blood Flow (CBF).- 2. Clinical Rating Scales.- 3. Psychometric Tests.- 4. Electroencephalography.- VII. Co-Dergocrine in Various Cardiovascular and Cerebral Indications.- 1. Arterial Hypertension.- 2. Shock.- 3. Stroke.- 4. Inner-Ear Disorders.- 5. Tardive Dyskinesia.- VIII. Biopharmaceutical Aspects.- IX. Toxicologic Considerations.- References.
